Group 1 - The company is developing two drugs, JX11502 and hydrochloride calirizine, both targeting schizophrenia indications, raising questions about the necessity of duplicative research and clinical trials [2] - The company responded on an investor interaction platform, stating that it will pursue a differentiated strategy in the schizophrenia sub-indications [2]